FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384301170> ?p ?o ?g. }

• W4384301170 abstract "Abstract Background Hepatocellular carcinoma (HCC) is the second malignancy worldwide. POLA2 initiates DNA replication, regulates cell cycle and gene repair that promote tumorigenesis and disease progression. However, the prognostic and biological function roles of POLA2 in HCC had not been conclusively determined. Methods The expression levels and prognosis role of POLA1 and POLA2 in HCC were analyzed based on TCGA-LIHC database and recruited 24 HCC patients. Gene mutations were analyzed using “maftools” package. POLA2 and immune cells correlations were analyzed by TIMER. POLA2 co-expressed genes functional enrichment were evaluated using Metascape. The mRNA and protein level of POLA2 was detected in HCC cells and tissues. Cell migration, invasion, proliferation, cell cycle and HCC cell lines derived xenograft model were performed to investigate POLA2 biological function. Results POLA2 was significantly high expressed in HCC than in normal liver tissue in both TCGA-LIHC and our collected HCC samples. In validation cohort, POLA2 significantly related to tumor differentiation, tumor size and Ki-67 (p < 0.05). In TCGA-LIHC cohort, overexpression of POLA2 predicted a low OS and associated with different clinical stages. Multivariate Cox regression showed overexpression of POLA2 effectively distinguished the prognosis at different T, N, M, stages and grades of HCC. POLA2 expression correlated with mutation burden, immune cells infiltration and immune-associated genes expression of HCC. Functional enrichment revealed that POLA2 co-expressed genes were linked to cellular activity, plasma membrane protein complex and leukocyte activity, immune response-regulated cell surface receptor signaling pathway, and immune response-regulated signaling pathway. Moreover, POLA2 was also positively co-expressed with some immune checkpoints (CD274, CTL-4, HAVCR2, PDCD1, PDCD1LG2, TIGIT, and LAG3) (p < 0.001). Gene knockdown revealed that POLA2 promoted proliferation, migration, invasion, and cell cycle of SMMC-7721 and HepG2. The HCC xenograft tumor model also demonstrated remarkably tumor size inhibition, tumor proliferation inhibtion and tumor necrosis promotion when POLA2 knockdown. Conclusions POLA2 influenced immune microenvironment and tumor progression of HCC indicated that it might be a potential molecular marker for prognostic evaluation or a therapeutic target for HCC." @default.
• W4384301170 created "2023-07-15" @default.
• W4384301170 creator A5019397177 @default.
• W4384301170 creator A5024937410 @default.
• W4384301170 creator A5040793026 @default.
• W4384301170 creator A5056302674 @default.
• W4384301170 creator A5070896899 @default.
• W4384301170 creator A5077963200 @default.
• W4384301170 creator A5081595944 @default.
• W4384301170 creator A5085536599 @default.
• W4384301170 creator A5091180311 @default.
• W4384301170 date "2023-07-14" @default.
• W4384301170 modified "2023-10-11" @default.
• W4384301170 title "Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis" @default.
• W4384301170 cites W1751875726 @default.
• W4384301170 cites W1964985165 @default.
• W4384301170 cites W1966107523 @default.
• W4384301170 cites W2015049472 @default.
• W4384301170 cites W2020302422 @default.
• W4384301170 cites W2022495797 @default.
• W4384301170 cites W2053762560 @default.
• W4384301170 cites W2058648826 @default.
• W4384301170 cites W2062351247 @default.
• W4384301170 cites W2069092694 @default.
• W4384301170 cites W2078485114 @default.
• W4384301170 cites W2100086304 @default.
• W4384301170 cites W2115094537 @default.
• W4384301170 cites W2121833624 @default.
• W4384301170 cites W2285022541 @default.
• W4384301170 cites W2406287421 @default.
• W4384301170 cites W2410455097 @default.
• W4384301170 cites W2469041829 @default.
• W4384301170 cites W2566002255 @default.
• W4384301170 cites W2609983368 @default.
• W4384301170 cites W2612910794 @default.
• W4384301170 cites W2619780686 @default.
• W4384301170 cites W2626033245 @default.
• W4384301170 cites W2755988260 @default.
• W4384301170 cites W2787215923 @default.
• W4384301170 cites W2790516087 @default.
• W4384301170 cites W2791082369 @default.
• W4384301170 cites W2807322325 @default.
• W4384301170 cites W2890306734 @default.
• W4384301170 cites W2896872272 @default.
• W4384301170 cites W2922356294 @default.
• W4384301170 cites W2928665623 @default.
• W4384301170 cites W2944933896 @default.
• W4384301170 cites W2977409903 @default.
• W4384301170 cites W2992211060 @default.
• W4384301170 cites W2999303877 @default.
• W4384301170 cites W3000803398 @default.
• W4384301170 cites W3004385008 @default.
• W4384301170 cites W3027286012 @default.
• W4384301170 cites W3034389835 @default.
• W4384301170 cites W3040967714 @default.
• W4384301170 cites W3080687659 @default.
• W4384301170 cites W3101090048 @default.
• W4384301170 cites W3108146310 @default.
• W4384301170 cites W3110236571 @default.
• W4384301170 cites W3119311457 @default.
• W4384301170 cites W3119973322 @default.
• W4384301170 cites W3152534107 @default.
• W4384301170 cites W3159664125 @default.
• W4384301170 cites W3162538759 @default.
• W4384301170 cites W3169908766 @default.
• W4384301170 cites W3173031257 @default.
• W4384301170 cites W3185745655 @default.
• W4384301170 cites W3214652428 @default.
• W4384301170 cites W4200388794 @default.
• W4384301170 cites W4210774372 @default.
• W4384301170 cites W4210955410 @default.
• W4384301170 cites W4221012464 @default.
• W4384301170 doi "https://doi.org/10.1186/s12935-023-02949-z" @default.
• W4384301170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37452331" @default.
• W4384301170 hasPublicationYear "2023" @default.
• W4384301170 type Work @default.
• W4384301170 citedByCount "1" @default.
• W4384301170 crossrefType "journal-article" @default.
• W4384301170 hasAuthorship W4384301170A5019397177 @default.
• W4384301170 hasAuthorship W4384301170A5024937410 @default.
• W4384301170 hasAuthorship W4384301170A5040793026 @default.
• W4384301170 hasAuthorship W4384301170A5056302674 @default.
• W4384301170 hasAuthorship W4384301170A5070896899 @default.
• W4384301170 hasAuthorship W4384301170A5077963200 @default.
• W4384301170 hasAuthorship W4384301170A5081595944 @default.
• W4384301170 hasAuthorship W4384301170A5085536599 @default.
• W4384301170 hasAuthorship W4384301170A5091180311 @default.
• W4384301170 hasBestOaLocation W43843011701 @default.
• W4384301170 hasConcept C104317684 @default.
• W4384301170 hasConcept C126322002 @default.
• W4384301170 hasConcept C1491633281 @default.
• W4384301170 hasConcept C203014093 @default.
• W4384301170 hasConcept C2778019345 @default.
• W4384301170 hasConcept C2779399171 @default.
• W4384301170 hasConcept C29537977 @default.
• W4384301170 hasConcept C502942594 @default.
• W4384301170 hasConcept C54355233 @default.
• W4384301170 hasConcept C555283112 @default.
• W4384301170 hasConcept C71924100 @default.
• W4384301170 hasConcept C86803240 @default.

• next